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Abstract Human induced pluripotent stem cells (hiPSCs)
have demonstrated great potential for hyaline cartilage regen-
eration. However, current approaches for chondrogenic dif-
ferentiation of hiPSCs are complicated and inefficient primar-
ily due to intermediate embryoid body formation, which is
required to generate endodermal, ectodermal, andmesodermal
cell lineages. We report a new, straightforward and highly
efficient approach for chondrogenic differentiation of hiPSCs,
which avoids embryoid body formation. We differentiated
hiPSCs directly into mesenchymal stem /stromal cells
(MSC) and chondrocytes. hiPSC-MSC-derived chondrocytes
showed significantly increased Col2A1, GAG, and SOX9
gene expression compared to hiPSC-MSCs. Following trans-
plantation of hiPSC-MSC and hiPSC-MSC-derived
chondrocytes into osteochondral defects of arthritic joints of
athymic rats, magnetic resonance imaging studies showed
gradual engraftment, and histological correlations demonstrat-
ed hyaline cartilage matrix production. Results present an
efficient and clinically translatable approach for cartilage tis-
sue regeneration via patient-derived hiPSCs, which could
improve cartilage regeneration outcomes in arthritic joints.
Keywords Pluripotent stem cell .Mesenchymal stem/stromal
cell . Cartilage tissue engineering .MRI (magnetic resonance
imaging) . Osteoarthritis
Introduction
Osteoarthritis (OA) is a major cause of disability, affecting
about 43 million individuals in the US [1] and resulting in
significant medical costs and lost wages reaching up to $95
billion per year [2]. Permanent articular cartilage defects,
characterized by deterioration of the collagen matrix and
depletion of aggrecan and type 2 collagen, represent the
primary cause of OA [3], and are difficult to treat because
cartilage cannot self-regenerate [4]. To address this problem,
chondrocyte and bone marrow derived stem cell transplants
have been explored as a therapeutic option for cartilage re-
generation. However, both cell types are limited by several
drawbacks, including an insufficient number of collectable
donor cells, invasiveness of the harvesting procedure, and
tendency of these cell types to form undesired fibrocartilage
[5].
Pluripotent stem cells have demonstrated great potential for
restoration of desired hyaline cartilage [6]. Recently, autolo-
gous human induced pluripotent stem cells (hiPSCs),
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generated from adipose-derived stem cells (ASCs) [7] or
fibroblasts [8, 9] using virus independent reprogramming
techniques, have been introduced as a clinically applicable
source for creation of patient-specific cartilage [10, 11]. Un-
like allogeneic cells, autologous hiPSCs do not engender
immune reactions, and unlike embryonic stem cells, they do
not raise ethical concerns [9, 12]. In addition, hiPSCs over-
come limitations associated with autologous bone marrow-
derived stem cells, such as invasive harvesting procedures,
variable yields, and restricted cartilage regeneration potential
of cells obtained from older patients [13].
While hiPSCs have shown promise for cartilage defect
repair, the complex and inefficient process used to differenti-
ate hiPSCs to cartilage limits the clinical translation of this
approach [14]. The most frequently used technique requires
three main steps: (1) formation of suspension embryoid bod-
ies; (2) mesenchymal stem/stromal cell (MSC) outgrowth
from embryoid bodies; and (3) selection of MSC via cell
sorting and induction of chondrogenic differentiation [14]
[15], (Fig. 1). This approach is highly inefficient, as it leads
to a variable number and size of embryoid bodies, which are
composed of heterogeneous cell populations, and results in
unpredictable differentiation to undesired cell lines [16]. We
hypothesized that eliminating embryoid body formation as an
intermediate step in the differentiation process could reduce
generation of unwanted cell lines and improve the yield of
chondrocytes.
Thus, the goal of our study was to develop a novel ap-
proach for differentiation of hiPSCs that sidesteps embryoid
body formation and improves the efficiency of chondrocyte
production from hiPSCs. In contrast to prior work on chon-
drocyte differentiation, our approach involves direct induction
of human mesenchymal stem/stromal cells (hMSCs) under
specific cell culture conditions, followed by classic
chondrogenic differentiation (Fig. 1). Our approach is superior
over its predecessors because it bypasses differentiation into
undesired cell types. This could be exploited as a framework
for more efficient and better controlled design of new cellular
therapeutics for cartilage regeneration. Our technique could be
also widely applied to other pluripotent stem cells (e.g., ESCs)
and other differentiation pathways, beyond our own focus of
cartilage regeneration.
Materials and Methods
hiPSC Culture and Pluripotency Evaluation
The study was approved by the Committee on Human Re-
search and the Stem Cell Research Oversight (SCRO)
Fig. 1 Chondrogenic differentiation of hiPSC. (a) Classical
chondrogenic differentiation of hiPSCs via formation of embryoid
bodies, outgrowth of endodermal (green), ectodermal (yellow) and
mesodermal (red) cell lineages, selection of mesodermal cells, and
induction of MSC and induction of chondrocytes. In this method hiPS
cells were detached from matrigel coated dish and moved to ultra low
attachment culture dish for 5 days to induce the EB formation, then EBs
moved to plastic culture dish to select the hMSCs by collecting the
outgrowing cells from EB (from day 5 to day 14) after collecting the
attached fibroblast-like cells. These cells were cultured for 3 weeks in
media containing FBS to prepare the hiPSC-MSCs (day 35 of
differentiation). Then, hiPSC-MSCs were differentiated in a pellet
culture system using serum free chondrogenic media for 3 weeks. (b)
Embryoid body free method of direct differentiation of hiPSCs into
hiPSC-MSCs, followed by chondrogenic differentiation. In embryoid
body free method hiPSCs were cultured in matrigel coated dish and
media was changed to hMSC media (DMEM supplemented with FBS)
for 5 days to induce the hMSC differentiation (Day 5). Then, cells were
detached and moved to a plastic culture dish for 4 passages to prepare the
hiPSC-MSCs (Day 28). To differentiate the hiPSC-MSCs to
chondrocytes, cells were used in pellet culture system using serum free
chondrogenic media for 3 weeks
Stem Cell Rev and Rep (2015) 11:242–253 243
Committee at our institution. Integration-free hiPSCs were
derived from either adipose-derived stem cells (ACSs) using
the previously describedminicircle reprogramming technique,
or from fibroblasts using a new optimized minicircle back-
bone [7]. hiPSCs derived from two different sources were
used to proof that our iPS-MSC differentiation method can
be applied to different hiPS cell types. In brief, to induce
pluripotency we transfected (electroporation) 12 μg of codon
optimized minicircle plasmids into 1×106 adult human fibro-
blasts and plated the cells onMatrigel coated plates in DMEM
10 % FBS. On the following day, we changed the media with
DMEM 10 % FBS plus 10 μm sodium butyrate and ascorbic
acid (50 μg/ml). After 5 days we changed to chemical defined
media E6 plus FGF2 (100 ng/ml). The first hiPSC colonies
appeared after 30 days and were picked individually. There-
after the undifferentiated hiPSCs were cultured in chemical
defined conditions either in mTeSR1™ medium (Stem Cell™
Technologies, Vancouver, BC, Canada) or E8 (Life Technol-
ogies, Carlsbad, CA, USA) in 10 cm petri dishes (BD Falcon,
Sparks, MD, USA) coated with 1 % matrigel (BD Matrigel™
Basement Membrane Matrix) at 37 ° C in a 5 % CO2 atmo-
sphere. The medium was changed every day and cells were
sub-cultured every 4–5 days using Accutase. Pluripotency of
the hiPSCs were evaluated by immune-staining for
pluripotency markers OCT4, SOX2, NANOG, and TRA-1-
60 (Fig. 2a). A subcutaneous injection of hiPSCs was per-
formed in severe combined immunodeficient (SCID) mice to
evaluate the pluripotency phenotype of the hiPSCs. The
Fig. 2 Pluripotency evaluation
and teratoma formation of
hiPSCs. (a) Immunofluorescence
staining with DAPI counterstain
demonstrating positive
pluripotency markers NANOG,
OCT4, SOX2, and TRA-1-60. (b)
H&E stains of a representative
hiPSC-derived teratoma confirm
pluripotency of the hiPSCs with
presence of all three germ layers,
including ectoderm, mesoderm,
and endoderm. (scale bar=
400 μm)
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resulting teratomas were sectioned and stained to verify all
three germ layers’ differentiation, including endoderm, meso-
derm, and ectoderm (Fig. 2b).
hiPSC Differentiation into hiPSC MSC Cells
In vitro experiments were performed for both ASC-derived
and fibroblast-derived hiPSCs. hiPSCs were differentiated
into MSCs as shown in Fig. 2; Undifferentiated hiPSCs were
cultured to reach 50 % confluency; Subsequently, the
mTeSR1™/E8 media was changed to typical hMSC culture
medium such as high glucose Dulbecco’s Modified Eagle
Medium (DMEM, Life Technologies, Carlsbad, CA, USA)
with 10 % stem cell-qualified fetal bovine serum (FBS, Life
Technologies, Carlsbad, CA, USA), 100 units/mL of Penicil-
lin, and 100 mg/mL of Streptomycin (Life Technologies,
Carlsbad, CA, USA). The DMEM high-glucose medium
was changed every day for 5 days. On day 5, cells were
detached from the matrigel-coated petri dishes using 5 %
Trypsin/EDTA (Life Technologies, Carlsbad, CA, USA) and
cultured on uncoated polysterene culture flasks (Fisher Scien-
tific Company, Pittsburgh, PA, USA). The medium was
changed every other day until the cells reached 90 %
confluency. The cells were then sub-cultured at a ratio of 1:3
until passage 4 (P4). The cell morphology of original hiPSCs,
hiPSC-MSCs, and bone marrow derived MSCs were ob-
served by phase contrast imaging over time (Fig. 3a).
Phenotyping of hiPSC-MSC Cells
In order to characterize the phenotypes of the differentiated
hiPSC-MSCs, triplicate samples of hiPSCs and hiPSC-MSCs
underwent flow cytometry analyses on a BD FACS Canto II
flow cytometer. Compensation was set using BD Comp
Beads. The cells were tested for MSC markers according to
the International Society for Cell Therapy (ISCT) [17] criteria,
which included the presence of CD105, CD73, and CD90, as
well as the lack of CD45, CD34, CD14 or CD11b, CD19 and
HLA-DR surface molecules. Briefly, cells were stained using
hMSC Analysis kit (BD Biosciences, CA) according to man-
ufacturer instruction. Data were analyzed using BD FACS
Diva software (BD Biosciences, San Jose, CA, USA) and
Flowjo™ data analysis package (http://www.Treestar.com).
Plur ipotency markers of the hiPSC-MSCs were
Fig. 3 Morphology and Phenotypes of hiPSC-derived hiPSC-MSC cells.
(a) Changes in cell morphology during hiPSC differentiation: Day 0:
Dome-shaped hiPSC colony; Day 1: Changing the mTeSR1™/E8
medium to hMSC medium leads to differentiation and out-growth of
the cells from the colonies; Day 5: After sub-culture to uncoated and
untreated culture flasks, the pre-differentiated cells attach to the
polystyrene flask and start to form an elongated morphology. Day 21:
At passage 4, cells show a spindle shape morphology, similar to hMSCs.
(scale bar left panel=400 and right panel 200 μm). (b) Flow cytometry
analysis of surface markers of hiPSCs and hiPSC-MSCs at passage 4
shows positive hMSC surface markers of CD105, CD73, and CD90, and
lack of CD45, CD34, CD14 or CD11b, CD19 and HLA-DR surface
molecules according to the International Society for Cell Therapy (ISCT)
criteria
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evaluated by immune-staining for pluripotency markers
OCT4, SOX2, NANOG, and TRA-1-60.
Chondrogenic Differentiation of hiPSC in vitro
To evaluate the chondrogenic potential of the hiPSC-derived
MSCs in vitro, the cells were detached from culture flasks
using 5 % Trypsin/EDTA and underwent chondrogenic dif-
ferentiation in a 3D, high-density pellet culture using
established protocols [18]. In brief, centrifuged pellets of
2.5×105 hiPSC-derived MSCs were incubated in 5 % CO2
at 37 ° C and in 0.5 mL of serum-free chondrogenic differen-
tiation medium, consisting of high glucose DMEM, 100
U/mL penicillin, 100 μg/mL streptomycin, 10% L-Glutamine
(Gibco), 50 μg/mL L-ascorbic acid 2-phosphate
sequimagnesium (Sigma), 100 μg/mLMEM sodium pyruvate
(Gibco), 40 μg/mL L-Proline (Sigma), 100 nM dexametha-
sone (Sigma), ITS+Premix final concentration: 5.5 μg/mL
transferring, 10 μg/mL bovine insulin, 5 μg/mL sodium sel-
enite, 4.7 μg/mL linoleic acid, and 500 μg/mL bovine serum
albumin (BD Bioscience, Franklin Lakes, NJ), and supple-
mented with 10 ng/mLTGF-β3 (R&D Systems, Minneapolis,
MN). The chondrogenic medium was changed every other
day for 21 days. Pellets were harvested on days 0, 7, and 14 of
chondrogenic differentiation for gene expression analysis and
day 21 for standard histopathology and immunohistochemistry.
Quantitative real-time PCR (qPCR) was used to further
confirm chondrogenic differentiation of the hiPSC-derived
MSCs. Gene expression levels of the differentiated cells
were assessed for hyaline cartilage markers (collagen type
II (Col2A1), collagen type IX, collagen type XI, SRY (sex
determining region Y)-box 9 (SOX9), and Aggrecan
(ACAN)), fibrocartilage marker (collagen type I), hyper-
trophic cartilage (collagen type X), and the control marker
of Glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
The primer sequences presented in Table 1. In brief, the
total cellular RNAwas extracted from each sample with the
QIAGEN RNeasy® mini kit. Samples of cDNA were pre-
pared from total RNA samples and qPCR was carried out
on an Applied Biosystems StepOne™ Real-Time PCR Sys-
tem. The formation of double-stranded DNA was moni-
tored by TaqMan® gene expression primers. Expression
data were collected as Ct values and the gene expression
levels were normalized to the reference control gene,
GAPDH.
To investigate the Aggrecan and Collagen type II produc-
tion of the cells, Alcian blue and immunohistochemistry stain-
ing were performed. The chondrogenic pellets were fixed in
10 % neutral buffered formalin (VWR, PA, USA), dehydrated
through graded alcohol washes (70, 95 and 100%) and xylene
(EMD, Millipore, USA), embedded in paraffin and sectioned
into 5 μm thick tissue slices on glass slides. The slides were
de-waxed to undergo Hematoxylin and Eosin (H&E) staining
for evaluation of cell morphology, Alcian blue staining for
detection of proteoglycan production, and immunohistochem-
istry for Collagen type II detection. For Collagen type II
immunohistochemistry, tissue sections were pre-digested with
pepsin (1 mg/mL in Tris–HCl, pH 2.0), incubated with the
anti-collagen II primary antibody (Chemicon, 1:500) for
60 min, followed by biotinylated goat anti-mouse antibody
for 30 min and streptavidin peroxidase for 45 min at room
temperature. Sections were visualized with DAB chromogen,
counterstained with Hematoxylin for 3 min, dehydrated, and
mounted with Permount solution.
Table 1 Reference and target
gene primer sequences used in
qPCR experiments
Gene name Sequence
(F: Forward / R: Reverse)
Catalogue number Reference
GAPDH* F: 5′ CGCTCTCTGCTCCTCCTGTT 3′
R: 5′ CCATGGTGTCTGAGCGATGT 3′
Hs02758991_g1 NM_001256799
ACAN F: 5′ AGGCAGCGTGATCCTTACC 3′
R: 5′ GGCCTCTCCAGTCTCATTCTC 3′
Hs00153936_m1 NM_001135
SOX9 F: 5′ GTACCCGCACTTGCACAAC 3′
R: 5′ TCTCGCTCTCGTTCAGAAGTC 3′
Hs01001343_g1 NM_000346
COL2A1 F: 5′ CGTCCAGATGACCTTCCTACG 3′
R: 5′ TGAGCAGGGCCTTCTTGAG 3′
Hs00264051_m1 NM_001844
COL1A2 F: 5′ CAGGAAACAGCTATGACC 3′
R: 5′ CTACTCTCAGCCCAGGAGGTCCTG 3′
Hs01028969_m1 NM_000089
COL9A1 F: 5′ TGTAAAACGACGGCCAGT 3′
R: 5′ CAGGAAACAGCTATGACC 3′
Hs00932129_m1 NM_001851
COL10A1 F: 5′ GGCAGAGGAAGCTTCAGAAA 3′
R: 5′ AAGGGTATTTGTGGCAGCATA 3′
Hs00166657_m1 NM_000493
COL11A1 F: 5′ TGTAAAACGACGGCCAGT 3′
R: 5′ CAGGAAACAGCTATGACC 3′
Hs01097664_m1 NM_001190709
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Osteogenic and Adipogenic Differentiation of hiPSC in vitro
To evaluate the osteogenic and adipogenic potential of the
hiPSC-MSCs in vitro, the cells were detached from culture
flasks using 5 % Trypsin/EDTA and underwent differentia-
tion. Osteogenic differentiation was induced by culturing 6×
104 cells/cm2 in osteogenic differentiation medium consisting
of DMEM supplemented by 10 % FBS (Gibco), 100 U/ml
penicillin, 100 μg/ml streptomycin (Gibco), 10 % L-Gluta-
mine (Gibco), 50 μg/ml L-ascorbic acid 2-phosphate
sequimagnesium (Sigma), 100 μg/ml MEM sodium pyruvate
(Gibco), 0.1 μM dexamethasone (Sigma), and 100 mM b-
glycerophosphate. Adipogenic differentiation was induced by
culturing 3×105 cells/cm2 in adipogenic medium consisting
of DMEM supplemented with 10% FBS, 100 U/ml penicillin,
100 μg/ml streptomycin (Gibco), 10 % glutamax (Gibco),
100 μg/ml insulin (Sigma), 500 μM 3-isobuthy-l-
methylxanthine (IBMX), 100 μM indomethacin and 1 μM
dexamethasone (Sigma). The medium was changed every 3–
4 days for 3 weeks.
Histological evaluation of osteogenic differentiation was
evaluated using Alizarin Red S stain. Cells were stained with
the 2 % Alizarin Red S solution (pH 4.1 ~4.3) for 5 min at
room temperature, and the reaction were observed microscop-
ically. Cells were washed with distilled water to remove the
excess stains. Calcium deposits in differentiated cells would
produce red-orange stains.
Histological evaluation of adipogenic differentiation was
determined using 0.3 % Oil Red O stain for 15 min at room
temperature to stain intracellular lipids, and counterstained
with hematoxylin. Fat vacuoles in differentiated cells would
produce red stains.
Engraftment of hiPSC-derived MSCs and Chondrogenic
Pellets in rat Knee Joints
In vivo experiments were performed with hiPSC-MSC differ-
entiated from ASC derived hiPSC only. To evaluate in vivo
engraftment and exclude in vivo teratoma formations, hiPSC-
MSCs and chondrocytes were implanted into osteochondral
defects of rat knee joints and evaluated with MR imaging and
histopathology. The animal experiments were approved by the
animal care and use committee at our institution.
Osteochondral defects were created in the distal femoral troch-
lear groove of 9 knee joints of 5 athymic nude Sprague
Dawley rats, using a micro-drill (Flash DP Tabletop
Micromotor, DBI America Corp, FL, USA). 2.5×105
hiPSC-derived MSCs (3 knees) or 2.5×105 hiPSC-derived
chondrogenic differentiated cell pellets after 3 weeks of dif-
ferentiation (3 knees) in 2 μl of Polyethylene Glycol (PEG)
and chondroitin sulfate methacrylate (CS) based scaffold were
implanted into the femoral defect. Scaffold-only implants (3
knees) served as controls.
The PEG-CS scaffold was prepared afresh every time
before the cell implantation by mixing 14 μl of 10 %
PEG3K-DMA solution with 6 μl of 10 % CS solution. Di-
rectly before implantation, cells in PEG-CS were mixed with
2.4 μl of polymerizing solution (containing two parts of
Ammonium Persulfate (APS) solution (1 M) and one part of
tetramethylethylenediamine (TMEDA) solution (1 M)), and
immediately injected to the defect. The cell-seeded scaffold
polymerized within 2 min.
To exclude teratoma formation and investigate the engraft-
ment of cell implants over time, all knee joints underwent MR
imaging immediately following stem cell transplantation as
well as 3 weeks and 6 weeks after transplantation. MR imag-
ing was performed on a 7 Tesla MR scanner (General Electric
“microSigna 7.0”) using a single-channel transmit/receive
partial birdcage radiofrequency coil. Sagittal MR images of
the rat knees were obtained with a fast spin echo (FSE)
sequence (Repetition time, TR: 3000 ms, Echo time, TE:
30 ms) and a multi-echo spin echo (SE) sequence (TR
4000 ms /TE 15, 30, 45, 60 ms), using a field-of-view
(FOV) of 2.5×2.5 cm, a matrix of 256×256 pixels, and a
slice thickness of 0.5 mm. Because successful engraftment has
been characterized by a significant decline in T2-relaxation
times of cell implants in cartilage defects [19], we generated
pixel-wise T2 relaxation time maps of cell implants using
custom research software (Cinetool, GE Global Research
Center, Niskayuna, NY). T2 relaxation times of each cell
implant was measured on these maps via operator-defined
regions of interests (ROIs). After the last MR scan, animals
were sacrificed and specimens were processed for postmortem
histopathology correlations, which included H&E stains, im-
munohistochemistry for collagen type II, and Alcian blue
stains. ICRS (International Cartilage Repair Society) visual
histological assessment scale was used as a standard histolog-
ical grading to quantify the extent of cartilage repair (Table 2).
Engraftment and long term viability of the implanted cells
evaluated by human anti-nuclear specific immunofluorescent
stain (MAB1281 | Anti-Nuclei Antibody, EmdMillipore) that
was performed on the rat knee samples.
Data Analysis
Gene expression levels of original hiPSCs, intermediate
hiPSC-derived MSCs as well as chondrogenic pellets at days
0 and 14 of chondrogenic differentiation were compared using
an analysis of variance (ANOVA). A Bonferroni correction
was applied for comparisons. An analysis of variance
(ANOVA) with a Bonferroni correction was used to compare
MRI T2 relaxation times of each groups overtime, and the T2
relaxation times of the scaffold-only group were compared
with hiPSC-derived MSC and hiPSC chondrogenic differen-
tiated cell pellets groups. All statistical analyses were
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performed using GraphPad Prism 6 statistical software
(GraphPad Software Inc. CA, USA).
Results
Generation of hiPSC-MSCs from hiPSCs
Without Intermediate Embryoid Body Formation
In order to enable clinical use, it is important to use hiPSC-
derived cell products without viral integrations. Therefore, we
generated hiPS cell lines from human adipose derived stem
cells, using the minicircle reprogramming technique [7]. For
generation of hiPS cell lines from adult human fibroblasts, we
used a codon-optimized minicircle plasmid [20] (Diecke et al.
2014). The pluripotency of the generated hiPSCs was con-
firmed by positive immunofluorescence staining for NANOG,
OCT4, SOX2, and TRA-1-60 (pluripotency markers)
(Fig. 2a). In addition, H&E stains of hiPSC-derived teratomas
showed differentiation into all three germ layers, including
ectoderm, mesoderm, and endoderm (Fig. 2b).
To initiate hMSC-induction, undifferentiated hiPSCs were
cultured in DMEM high-glucose medium for 5 days, followed
by transfer to uncoated polysterene culture flasks, continued
culture until 90 % confluency and sub-culture at a ratio of 1:3
until passage 4 (P4).
The change of mTeSR1™/E8 medium to hMSC medium
resulted in a change in cell morphology from dome-shaped
hiPSC colonies to elongated and spindle-shaped cells, which
spread out from their original colonies. Although the cells
demonstrated a heterogeneous morphology on the first and
second day ofMSC-induction, more than 90% of the total cell
population acquired a fibroblast-like morphology by passage
4, matching the typical morphology of hMSCs (Fig. 3a). To
determine phenotypes and genotypes of hiPSC-derived
MSCs, we performed standard microscopy and flow cytome-
try analysis. The flow cytometry analysis showed that more
than 90 % of the cells were positive for the hMSC markers:
CD105 (>91 %), CD73 (>96 %), and CD90 (>95 %), and
negative for CD45, CD34, CD14 or CD11b, CD19, and HLA-
DR surface molecules (>95 %) (Fig. 3b). The results showed
that hiPSCs are positive for CD90 which is in accordance to
other researcher that suggested CD90 as one of the
pluripotency markers [21]. The differentiation of the generat-
ed hiPSC-MSCs was confirmed by negative immunofluores-
cence staining for pluripotency markers such as NANOG,
OCT4, SOX2, and TRA-1-60 (data not shown).
Alizarin Red S staining of the hiPSC-MSCs visualized the
calcium deposition of the cells after 21 days of osteogenic
differentiation induction which proves the osteogenic differ-
entiation potential of the hiPSC-derived MSCs. In addition,
Oil red O stain demonstrated that hiPSC- derived MSCs
exhibited developing of fat vacuoles after 21 days of
adipogenic differentiation (Fig. 4c).
Chondrogenic Differentiation of hiPSC-derived MSCs
To evaluate chondrogenic differentiation of hiPSC-derived
MSCs in vitro, we induced chondrogenic differentiation in a
3D, high-density pellet culture [18] and tested original hiPSCs,
hiPSC-derived MSCs and chondrogenic pellets for cartilage
markers. Col2A1, Col9A1, Col11A1, SOX9, and ACAN genes
were significantly increased in chondrogenic cell pellets at day
14 of differentiation, confirming the differentiation of the cells
towards chondrogenic lineage (p<0.001) (Fig. 4a). However,
additional upregulation of Co1A2 and Col10A1 indicates some
components of fibrocartilage and hypertrophic cartilage, respec-
tively (Fig. 4a). The histologic evaluation of the cell pellets at
day 21 of chondrogenic differentiation (day 42 on Fig. 1) con-
firmed cartilage tissue formation on H&E stains and positive
Alcian blue stains, indicating proteoglycan production (Fig. 4b).
In addition, collagen type II immunohistochemistry was positive
for chondrogenic pellets at day 21, indicating production of the
hyaline cartilage matrix (Fig. 4b).
Table 2 ICRS visual histological assessment scale
Feature Score
I. Surface
Smooth/continuous 3
Discontinuities/irregularities 0
II. Matrix
Hyaline 3
Mixture: hyaline/fibrocartilage 2
Fibrocartilage 1
Fibrous tissue 0
III. Cell distribution
Columnar 3
Mixed/columnar-clusters 2
Clusters 1
Individual cells/disorganized 0
IV. Cell population viability
Predominantly viable 3
Partially viable 1
<10 % viable 0
V. Subchondral Bone
Normal 3
Increased remodeling 2
Bone necrosis/granulation tissue 1
Detached/fracture/callus at base 0
VI. Cartilage mineralization (calcified cartilage)
Normal 3
Abnormal/inappropriate location 0
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In order to exclude teratoma formation and confirm
chondrogenic differentiation of hiPSC-derived MSCs
in vivo, hiPSC-derived MSCs and hiPSC-derived
chondrogenic cells (day 21) were implanted into
osteochondral defects of the distal femur of nude athymic
Sprague Dawley rats and evaluated with serial MR imaging
studies over a time period of 6 weeks. The MR imaging
evaluation did not show any evidence for teratoma formation
of hiPSC-derived MSCs or chondrogenic cells in vivo. The
cell transplants showed significantly decreasing T2 relaxation
times over time (p<0.001). This signal effect is an indication
for decreasing water content and increasing matrix
Fig. 4 Characterization of hiPSC-derived Chondrogenic Cells. (a)
Relative gene expression of hiPSC-derived hiPSC-MSCs at day 21
(equal to day 0 of chondrogenic differentiation) and chondrogenic cell
pellets at day 28 (equal to day 7 of chondrogenic differentiation) and 35
(equal to day 14 of chondrogenic differentiation), as determined by
qPCR. Data are displayed as means and standard errors of triplicate
experiments per sample. Cells at day 14 of chondrogenic differentiation
show significantly increased gene expression of the hyaline chondrogenic
markers COL2A1, COL9A1, COL11A1, SOX9, and aggrecan (ACAN)
compared to hiPSC-MSCs. They also show an increased expression of
COL1A2 and COL10A1 representative of fibro- and hypertrophic
cartilage respectively. (*** indicates p<0.001). (b) Histological
evaluation of hiPSC-derived chondrogenic cell pellets at day 42 (equal
to day 21 of chondrogenic differentiation); H&E stain shows
chondrocytes and formation of a chondrogenic matrix. Alcian blue stain
demonstrates positive glycosaminoglycan production, and
immunohistochemistry shows positive stains for Collagen type II. (left
100 μm, right 50 μm). (c) Histological evaluation of hiPSC-MSCs
osteogenic (upper panel) and adipogenic (lower panel) differentiation.
Alizarin Red S staining used for osteogenic differentiation evaluation and
Oil Red O staining used to assess the adipogenic differentiation of hiPSC-
MSCs after 3 weeks of differentiation
Stem Cell Rev and Rep (2015) 11:242–253 249
formation over time and has been associated with successful
engraftment as described by Trattnig et al. [19]. T2-
relaxation times of cell implants at 6 weeks post implanta-
tion were significantly lower compared to controls with
scaffold only implants (p ≤ 0.013) (Fig. 5) . This
corresponded on histopathology to higher cellularity and
degradation of the scaffold in the cell transplants compared
to scaffold only (Fig. 6, Table 3). H&E staining confirmed
the engraftment of hiPSC-derived MSC cells and hiPSC-
derived chondrogenic differentiated cell pellets in
osteochondral defects. hiPSC-derived MSC implants had
started to remodel the defect and to produce a chondrogenic
matrix, as evidenced by positive Alcian blue stains and
positive immunostains for collagen type II (Fig. 6). By
comparison, scaffold-only implants demonstrated no repair
of the defect. hiPSC-derived chondrogenic pellets showed
stronger GAG and collagen type II staining compared to
hiPSC-derived MSCs implants (Fig. 6). ICRS histological
scale assessment revealed that the overall histological score
of repaired cartilage were significantly higher in hiPSC-
chondrocytes comparing to hiPSC-MSC implants
(p<0.032). Moreover, matrix production of the hiPSC-
chondrocytes was significantly higher than hiPSC-MSC
implants (p<0.016).
Human anti-nuclear specific immunofluorescent stain con-
firmed the presence and long-term viability of the human cells
in the repaired cartilage tissue in the hiPSC-derived
chondrogenic cells (Fig. 6d).
Discussion
Our findings show that a new and simplified differentiation
protocol can be used to differentiate hiPSCs directly into
mesenchymal stromal cells, without intermediate embryoid
body formation, thereby providing a more efficient approach
for cartilage generation from hiPSC compared to standard
procedures. Our procedure yielded 90 % chondrocytes and
successfully repaired osteochondral defects in vivo.
hiPSCs offer several advantages for cartilage repair over bone
marrow-derived MSCs and chondrocytes [22]. Whereas
chondrocytes and most adult stem cells such as hMSC and
adipose derived stem cells (ADSCs) show decreasing prolifera-
tion and differentiation potential after 4 passages in culture [23],
while undifferentiated hiPSCs can be expanded indefinitely.
This allows for the generation of a high quantity of differentiated
progeny for high-throughput analysis before their transplanta-
tion into patients [24–26]. Embryonic stem cells are the only
other cell typewith a similar capacity for proliferation. However,
the allogeneic nature of embryonic stem cells may generate
immune reactions, which limits their potential for clinical appli-
cations [24]. By contrast, hiPSCs from minimally invasive
sources such as skin fibroblasts or fat cells allow for generation
of autologous engineered tissues, even from elderly patients
typically suffering from OA [27, 28].
Despite their potential advantages, the use of hiPSCs for
cartilage repair has been limited because of the inefficiency
and complexity of standard chondrogenic differentiation pro-
cesses. Standard protocols require co-culture of hiPSCs with
chondrocytes [29], which requires a surgery for chondrocyte
harvest, as well as culture of hiPSCs in complex differentia-
tion media, which contain multiple growth factors with un-
clear in vivo effects [30, 31]. In addition, the standard hiPSC
differentiation approach via embryoid body formation gives
rise to heterogeneous cell populations and unpredictable dif-
ferentiation outcome [32]. Mesenchymal lineage selection
from embryoid bodies is laborious and costly, providing com-
paratively low yields [33, 34].
Fig. 5 In vivo engraftment of hiPSC-derived MSCs and Chondrogenic
Cells. (a) Sagittal T2-weighted MR images of implants of scaffold only,
hiPSC-derived MSCs, and hiPSC-derived chondrogenic cells in
osteochondral defects of the distal femurs of rat knee joints.
Superimposed T2 relaxation time maps show decreasing T2 values of
transplanted cells, but not scaffold only, over time. (b) Corresponding
quantitative measures of T2-relaxation times of cell transplants and
scaffold only. Data are displayed as means and SE of triplicate
experiments. (* and ** indicates p<0.05 and p<0.01 respectively)
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Other investigators explored approaches for hiPSC differ-
entiation without embryoid body formation by culturing
hiPSCs as micromass formation (Saitta et al., 2014) [35],
under pellet culture conditions (Phillips et al., 2014) [36],
and using specific media on modified/coated culture flasks
and/or on feeder-layers [37]. These methods may impede
clinical translations by interfering with biomechanical proper-
ties of the substrate, suppressing cellular proliferation [38, 39],
negatively affecting related signaling pathways [40, 41], using
viral vectors to produce iPS cells, risk of mixing feeder layer
cells with final cells [36], or increasing costs compared to
standard techniques [42, 43]. Chen et al. reported that hiPSC
incubation with SB431542 (a specific inhibitor of TGF-β
receptor kinase) in two-dimensional cultures enabled MSC
conversion without embryoid body formation [44]. However,
their method required an intermediate step of epithelial differ-
entiation and the clinical safety and efficacy of SB431542 are
not yet established. By comparison, our method does not
require the use of a feeder-layer or coating, does not involve
either embryoid body formation or an endothelial conversion
step, and requires no additional chemicals to differentiate the
cells towards mesenchymal lineage.
We recognize several limitations of our study. Firstly, we
observed some components of fibrocartilage and hypertrophic
cartilage in our in vitro differentiation samples, which needs to
be improved for future use by optimizing the in vitro
chondrogenic differentiation induction method (e.g. by using
different combination of growth factors).. We also used fetal
bovine serum (FBS) as a supplement for cell culture, which
may increase the risk of cell transformation and prion dis-
eases. Substitution with fully defined serum-free media as
described by Yamasaki et al. will increase the safety of our
method for clinical applications [45]. Although we did not
observe teratoma formations in our cell transplants, hiPSCs
and hiPSC-derived progenies may have tumor potency in vivo
[24, 46]. In a clinical setting, careful phenotyping of hiPSC-
derived transplants will be necessary before implantation. To
reduce the potential for tumorigenic outgrow of hiPSC-
derived chondrocytes, we used the integration- and viral-free
Fig. 6 Histological evaluation of hiPSC-derived MSCs and
chondrogenic cells implanted in rat knee joints. (a) H&E stain of
chondrogenic differentiated hiPSC-derived MSCs shows persistent
defect after transplantation of scaffold only and engraftment of cell
implants with defect remodeling. (b) Alcian blue stain demonstrates no
glycosaminoglycan (GAG) production of scaffold only, mildly positive
GAG production of hiPSC-derived MSCs and markedly positive GAG
production of chondrogenic cells. (c) Collagen II immunohistochemistry
shows no production of Collagen type II in scaffold only and MSC
transplants, but markedly positive Collagen type II production after
transplantation of chondrogenic cells. (Arrow heads display the borders
of the defect and the complete arrows show the residual of scaffold; scale
bar is equal to 500 μm). (d) Human anti-nuclear specific
immunofluorescent stain shows presence and long term viability of the
human cells in the repaired tissue (Scale bar is equal to 50 μm)
Table 3 Histological results of cartilage repair of in vivo implants
Scaffold
only
hiPS-MSC hiPSC-
Chondrocyte
Surface 1 (1.73) 1 (1.73) 3 (0)
Matrix 0.34 (0.57) 1 (0) 2.34 (0.57)
Cell distribution 0.34 (0.57) 0.67 (0.57) 1.67 (0.57)
Cell population
viability
0 (0) 3 (0) 2.34 (1.15)
Subchondral Bone 1.34 (0.57) 1.67 (0.57) 2 (0)
Cartilage
mineralization
0 (0) 3 (0) 3 (0)
Overall 3 (1.73) 10.34 (0.57) 14.34 (2.08)
Data presented as mean score with standard deviation (SD)
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minicircle reprogramming technique. Although the
reprogramming efficiency of this technique is relatively low,
it prevents the potential reactivation of the pluripotency fac-
tors described for viral-derived hiPSCs and therefore lowers
the risk of subsequent tumor formation [47].
In summary, we have developed a novel and clinically
applicable approach for cartilage tissue regeneration via direct
differentiation of patient-specific hiPSCs to hMSCs, without
embryoid body formation. This approach could be widely
used for more efficient and better controlled design of new
cellular therapeutics for cartilage regeneration, thereby ulti-
mately restoring articular cartilage function in patients with
OA and decreasing associated morbidities. In the future, this
technique could be applied for many other tissue regeneration
applications, beyond our own focus on cartilage regeneration.
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